Pages that link to "Q43858400"
Jump to navigation
Jump to search
The following pages link to Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression (Q43858400):
Displaying 50 items.
- Stavudine, lamivudine and nevirapine combination therapy for treatment of HIV infection and AIDS in adults (Q24246038) (← links)
- Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1 (Q24802369) (← links)
- Outcome of protease inhibitor substitution with nevirapine in HIV-1 infected children (Q33378805) (← links)
- Dyslipidemia and adherence to the Mediterranean diet in Croatian HIV-infected patients during the first year of highly active antiretroviral therapy (Q33747646) (← links)
- Long-term CD4 T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI (Q33803473) (← links)
- Nevirapine once daily: pharmacology, metabolic profile and efficacy data of the new extended-release formulation (Q33850152) (← links)
- Nevirapine induced Stevens-Johnson syndrome in an HIV infected patient (Q34706519) (← links)
- Lipid Metabolism and Cardiovascular Risk in HIV-1 Infection and HAART: Present and Future Problems (Q34730407) (← links)
- Switching effective antiretroviral therapy: a review. (Q34985833) (← links)
- HIV and HAART-Associated Dyslipidemia (Q35020217) (← links)
- Randomised study to assess the efficacy and safety of once-daily etravirine-based regimen as a switching strategy in HIV-infected patients receiving a protease inhibitor-containing regimen. Etraswitch study (Q35087745) (← links)
- Strategies of HIV management — when to switch (Q35108730) (← links)
- Management of metabolic complications of therapy (Q35108739) (← links)
- Antiretroviral therapy for adults infected with HIV: Guidelines for health care professionals from the Quebec HIV care committee (Q35124959) (← links)
- Hypertriglyceridemia, Metabolic Syndrome, and Cardiovascular Disease in HIV-Infected Patients: Effects of Antiretroviral Therapy and Adipose Tissue Distribution (Q35176441) (← links)
- Hyperlipidaemia in patients with HIV-1 infection receiving highly active antiretroviral therapy: epidemiology, pathogenesis, clinical course and management (Q35202958) (← links)
- Quality of life in patients treated with first-line antiretroviral therapy containing nevirapine or efavirenz in Uganda: a prospective non-randomized study (Q35717749) (← links)
- Impact of switching antiretroviral therapy on lipodystrophy and other metabolic complications: a review (Q35805765) (← links)
- Clinical utility of current NNRTIs and perspectives of new agents in this class under development (Q35842270) (← links)
- Efavirenz for HIV-1 infection in adults: an overview (Q35917519) (← links)
- Lipid profiles in young HIV-infected children initiating and changing antiretroviral therapy (Q35926011) (← links)
- Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial (Q35965722) (← links)
- HIV-associated lipodystrophy syndrome: A review of clinical aspects (Q36171069) (← links)
- The nonnucleoside reverse transcriptase inhibitors efavirenz and nevirapine in the treatment of HIV. (Q36271415) (← links)
- Practical discussion on switching studies and how this relates to managing lipids (Q36292308) (← links)
- Evaluation of nevirapine-switch strategies for HIV treatment (Q36653843) (← links)
- Efavirenz: a review (Q36787311) (← links)
- WHO option B : early experience of antiretroviral therapy sequencing after cessation of breastfeeding and risk of dermatologic toxicity (Q37083642) (← links)
- Serious Non-AIDS events: Immunopathogenesis and interventional strategies (Q37418140) (← links)
- Antiretroviral therapy for children in resource-limited settings: current regimens and the role of newer agents (Q37925813) (← links)
- Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy (Q40512553) (← links)
- Outcome of neuropsychiatric symptoms related to an antiretroviral drug following its substitution by nevirapine: the RELAX study (Q41074891) (← links)
- Lipid-lowering effect and efficacy after switching to etravirine in HIV-infected patients with intolerance to suppressive HAART. (Q42276735) (← links)
- Better health-related quality of life after switching from a virologically effective regimen to a regimen containing efavirenz or nevirapine (Q43100446) (← links)
- Efficacy and safety of an NRTI-sparing dual regimen of raltegravir and ritonavir-boosted protease inhibitor in a triple antiretroviral class-experienced population (Q43228888) (← links)
- TRIZAL study: switching from successful HAART to Trizivir (abacavir-lamivudine-zidovudine combination tablet): 48 weeks efficacy, safety and adherence results (Q44408004) (← links)
- Strategies to optimize adherence to antiretroviral treatment. Interventions in the therapeutic regimen (Q44442989) (← links)
- Replacement of protease inhibitors by nevirapine or efavirenz in simplification and rescue interventions: which works better? (Q44547874) (← links)
- Meta-analysis of randomized controlled trials of simplified versus continued protease inhibitor-based antiretroviral therapy in HIV-1-infected patients (Q44644285) (← links)
- Long-term safety and efficacy of NNRTI within the central nervous system (Q44662447) (← links)
- Treatment of primary HIV-1 infection with nonnucleoside reverse transcriptase inhibitor-based therapy is effective and well tolerated (Q44734008) (← links)
- Differential CD4 T-cell response in HIV-1-infected patients using protease inhibitor-based or nevirapine-based highly active antiretroviral therapy. (Q44794025) (← links)
- Factors associated with efavirenz discontinuation in a large community-based sample of patients (Q44956373) (← links)
- Low trough plasma concentrations of nevirapine associated with virologic rebounds in HIV-infected patients who switched from protease inhibitors (Q45267389) (← links)
- Hepatotoxicity of antiretroviral drugs in HIV HCV patients with congenital coagulopathies followed at an Haemophilia Unit during a decade (Q45857827) (← links)
- Cardiovascular risk factors in patients on long-term treatment with nevirapine- or efavirenz-based regimens. (Q45907363) (← links)
- The Protease Inhibitor Transfer Study (PROTRA 1): abacavir and efavirenz in combination as a substitute for a protease inhibitor in heavily pretreated HIV-1-infected patients with undetectable plasma viral load (Q46474207) (← links)
- A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral load. (Q46698308) (← links)
- Comparison of neuropsychiatric side effects in an observational cohort of efavirenz- and protease inhibitor-treated patients (Q46743851) (← links)
- Effectiveness and safety of simplification therapy with once-daily tenofovir, lamivudine, and efavirenz in HIV-1-infected patients with undetectable plasma viral load on HAART. (Q46935128) (← links)